The HER Foundation continues the breakthroughs with publication of “Whole-exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum” in BJOG.
Dr. Marlena Fejzo, geneticist and HER’s Research Advisor and member of the Board of Directors, was featured in the Inverse article, “When morning sickness kills: doctors have dismissed hyperemesis gravidarum for decades, but new research could undo this harmful legacy.”
Help the HER Foundation show HG’s impact in May. Share your photos of HG treatments and challenges, so we can educate about what hyperemesis gravidarum (HG) is really like!
We frequently receive questions about why HG patients need more thiamin than their healthy counterparts. A pregnant Hyperemesis Gravidarum (HG) patient cannot eat a nutrient rich diet and may not be able to eat at all. A healthy pregnant patient can eat a nutrient rich diet that includes a variety of foods.
The HER Foundation’s breakthrough psychosocial study shows that Hyperemesis Gravidarum (HG) is not self limiting and has societal implications.
2021 has been a busy year for HER research, and we’re finding answers to your questions about Hyperemesis Gravidarum (HG). We’ve had papers published and given presentations. We also have papers under review in scientific journals, abstracts being reviewed for presentation at ACOG, new studies being kicked-off, and we are continuing ongoing research projects.
We put together this list of highlights from 2021! These are some of the people, the work, and the campaigns that made this HER’s best year yet! We are making Hyperemesis Gravidarum (HG) progress!
21 Years of Hyperemesis Gravidarum (HG) Impact was made possible by the support of our amazing community. And there is such hope for change. Don’t you feel it! Here at HER, we are ready for a BIG day in the nonprofit world: Giving Tuesday, November 30, 2021. Giving Tuesday (GT) is the largest giving day of the year, and we want to make this year’s GT our best yet!
The HER Foundation is thankful for our business partners who support our mission.
HER Board members, Marlena Fejzo, PhD, and Patrick Mullen, MD, are running the first study of GDF15 in HG patients in the United States.
